Novo A/S
Latest statistics and disclosures from Novo Holdings A/S's latest quarterly 13F-HR filing:
- Top 5 stock holdings are EWTX, ASML, Hemab Therapeutics Holdings, BN, MPLT, and represent 48.86% of Novo Holdings A/S's stock portfolio.
- Added to shares of these 8 stocks: Hemab Therapeutics Holdings (+$154M), Avalyn Pharma (+$128M), FND (+$47M), ALMS (+$31M), DYN (+$21M), INSM (+$13M), VRDN, BBOT.
- Started 6 new stock positions in DYN, FND, ALMS, Hemab Therapeutics Holdings, Avalyn Pharma, INSM.
- Reduced shares in these 10 stocks: APGE (-$38M), , MIRM (-$23M), AVBP (-$15M), ELVN (-$14M), PHVS (-$12M), CRNX (-$8.6M), VALN (-$6.6M), CLDX (-$6.5M), FDMT (-$5.3M).
- Sold out of its positions in APGE, BMRN, VALN.
- Novo Holdings A/S was a net buyer of stock by $226M.
- Novo Holdings A/S has $1.7B in assets under management (AUM), dropping by 39.54%.
- Central Index Key (CIK): 0001388325
Tip: Access up to 7 years of quarterly data
Positions held by Novo A/S consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Novo Holdings A/S
Novo Holdings A/S holds 25 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics (EWTX) | 12.6 | $217M | 5.4M | 40.63 |
|
|
| Asml Holding N V N Y Registry Shs (ASML) | 11.0 | $189M | 95k | 1989.44 |
|
|
| Hemab Therapeutics Hldgs Com Shs | 8.9 | $154M | NEW | 4.2M | 36.73 |
|
| Brookfield Corp Cl A Ltd Vt Sh (BN) | 8.7 | $150M | 3.5M | 42.77 |
|
|
| Maplight Therapeutics (MPLT) | 7.7 | $132M | 3.7M | 35.84 |
|
|
| Mirum Pharmaceuticals (MIRM) | 7.6 | $132M | -15% | 1.1M | 117.07 |
|
| Avalyn Pharmaceuticals Com Shs | 7.4 | $128M | NEW | 3.9M | 32.92 |
|
| salesforce (CRM) | 3.6 | $62M | 393k | 156.66 |
|
|
| Arrivent Biopharma (AVBP) | 3.0 | $52M | -22% | 1.5M | 34.74 |
|
| Enliven Therapeutics (ELVN) | 2.9 | $51M | -21% | 1.0M | 50.75 |
|
| Crinetics Pharmaceuticals In (CRNX) | 2.9 | $49M | -14% | 1.3M | 37.42 |
|
| Pharvaris N V (PHVS) | 2.8 | $48M | -20% | 1.4M | 34.58 |
|
| Floor & Decor Hldgs Cl A (FND) | 2.7 | $47M | NEW | 797k | 59.36 |
|
| Vaxcyte (PCVX) | 2.7 | $47M | -6% | 800k | 58.13 |
|
| 4d Molecular Therapeutics In (FDMT) | 2.5 | $43M | -10% | 3.2M | 13.30 |
|
| Miragen Therapeutics (VRDN) | 2.3 | $39M | +6% | 2.1M | 18.37 |
|
| Celldex Therapeutics Com New (CLDX) | 2.2 | $38M | -14% | 1.0M | 37.21 |
|
| Alumis (ALMS) | 1.8 | $31M | NEW | 1.1M | 28.14 |
|
| Xenon Pharmaceuticals (XENE) | 1.7 | $29M | 485k | 60.36 |
|
|
| Alibaba Group Hldg Sponsored Ads (BABA) | 1.4 | $25M | 257k | 95.98 |
|
|
| Dyne Therapeutics (DYN) | 1.2 | $21M | NEW | 960k | 22.21 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 1.0 | $17M | +2% | 2.3M | 7.62 |
|
| Insmed Com Par $.01 (INSM) | 0.7 | $13M | NEW | 121k | 106.62 |
|
| Marqeta Class A Com (MQ) | 0.4 | $7.2M | 442k | 16.24 |
|
|
| Lanzatech Global Com New (LNZA) | 0.1 | $1.1M | 158k | 6.82 |
|
Past Filings by Novo Holdings A/S
SEC 13F filings are viewable for Novo Holdings A/S going back to 2014
- Novo Holdings A/S 2026 Q2 filed Aug. 14, 2026
- Novo Holdings A/S 2026 Q1 filed May 15, 2026
- Novo Holdings A/S 2025 Q4 filed Feb. 17, 2026
- Novo Holdings A/S 2025 Q3 filed Nov. 14, 2025
- Novo Holdings A/S 2025 Q2 filed Aug. 14, 2025
- Novo Holdings A/S 2025 Q1 filed May 15, 2025
- Novo Holdings A/S 2024 Q4 filed Feb. 14, 2025
- Novo Holdings A/S 2024 Q3 filed Oct. 24, 2024
- Novo Holdings A/S 2024 Q2 restated filed Aug. 20, 2024
- Novo Holdings A/S 2024 Q1 filed May 15, 2024
- Novo Holdings A/S 2023 Q4 filed Feb. 14, 2024
- Novo Holdings A/S 2023 Q3 filed Nov. 14, 2023
- Novo Holdings A/S 2023 Q2 filed Aug. 14, 2023
- Novo Holdings A/S 2023 Q1 filed May 15, 2023
- Novo Holdings A/S 2022 Q4 filed Feb. 14, 2023
- Novo Holdings A/S 2022 Q3 filed Nov. 14, 2022